TABLE 2.

The agonists of PPARα under investigation.

Author	Disease	Drug (daily dose)	Drug combination	Treatment time (months)	Outcome	Side effect
Gallucci et al. (2021)	PBC and PSC	Fenofibrate (145–160 mg)	UDCA	1–53	ALP↓, AST↓, ALT↓, total serum BAs↓, serum BA‐glucuronides↑	None found
Sorda et al. (2021)	PBC	Bezafibrate (400 mg)	UDCA	60	ALP↓, AST↓, ALT↓, GGT↓, improvement of cirrhosis and fibrosis	None found
Reig et al. (2018)	PBC	Bezafibrate (400 mg)	UDCA	38	ALP normalization, jaundice↓, pruritus↓, liver stiffness↓	Transitory myalgi
Le moinne et al. (2018)	PSC	Fenofibrate (200 mg) or bezafibrate (400 mg)	UDCA	6	ALP↓, pruritus↓	None found
Tanaka et al. (2015)	PBC	Bezafibrate (400 mg)	UDCA	24	ALT normalization	None found
Hosonuma et al. (2015)	PBC	Bezafibrate (400 mg)	UDCA	110	ALP↓, Mayo risk score↓	Renal dysfunction, muscle pain
Lens et al. (2014)	PBC	Bezafibrate (400 mg)	UDCA	12	ALP↓, GGT↓, ALT↓, cholesterol↓, triglyceride↓, pruritus↓	Gastrointestinal discomfort, nausea, heartburn
Dohmen et al. (2013)	PBC	Fenofibrate (80 mg); Bezafibrate (400 mg)	UDCA	12	ALP↓, GGT↓, TG↓, LDL↓	None found
Han et al. (2012)	PBC	Fenofibrate (200 mg)	UDCA	3	ALP↓, GGT↓, TG↓, ALT↓, AST↓	None found
Levy et al. (2011)	PBC	Fenofibrate (160 mg)	UDCA	12	ALP↓, AST↓	Heartburn
Takeuchi et al. (2011)	PBC	Bezafibrate (400 mg)	UDCA	24	ALP↓	None found
Liberopoulos et al. (2010)	PBC	Fenofibrate (200 mg)	UDCA	2	ALP↓, GGT↓, ALT↓, cholesterol↓, TG↓	None found